Claims for Patent: 5,521,076

Summary for Patent: 5,521,076

Title:	Modified hepatocytes and uses therefor
Abstract:	Genetically engineered or transduced hepatocytes which express genetic material of interest introduced or incorporated into them, as well as methods of producing, transplanting and using the genetically engineered hepatocytes are disclosed. The genetic material of interest can be incorporated through the use of a vector, such as a recombinant retrovirus, which contains the genetic material of interest, or by other means.
Inventor(s):	Mulligan; Richard C. (Lincoln, MA), Wilson; James M. (Ann Arbor, MI)
Assignee:	Whitehead Institute For Biomedical Research (Cambridge, MA) Howard Hughes Medical Center (Bethesda, MD)
Application Number:	07/938,260
Patent Claims:	1. Transduced mammalian hepatocytes having genetic material of interest stably incorporated therein, the transduced hepatocytes being capable of in vivo expression of the polypeptide or protein encoded by the genetic material of interest wherein said genetic material comprises a retroviral vector lacking a selectable marker and selected from the group consisting of .alpha.-SGC and MFG. 2. Transduced mammalian hepatocytes of claim 1 in which the genetic material of interest is selected from the group consisting of: DNA which is present in and expressed by normal hepatocytes; DNA which does not normally occurs in hepatocytes but is not expressed in them at levels which are biologically significant; and any DNA which can be modified so that it can be expressed in hepatocytes. 3. Transduced mammalian hepatocytes of claim 2, wherein the genetic material of interest encodes a biologically active protein or polypeptide. 4. Tranduced mammalian hepatocytes of claim 3 wherein the genetic material of interest encodes human parathyroid hormone, tissue plasminogen activator, factor VIII, low density lipoprotein receptor or beta-galactosidase. 5. A method of making transduced mammalian hepatocytes which express stably incorporated genetic material lacking a selectable marker and encoding at least one protein of interest or at,least one polypeptide of interest, comprising the steps of: a) contacting the hepatocytes in vitro with media containing an infectious recombinant retrovirus having a recombinant genome comprising the "genetic material" for antecedent basis of interest wherein said genetic material comprises a retroviral vector lacking a selectable marker selected from the group consisting of .alpha.-SGC and MFG; and b) maintaining the hepatocytes and the media containing the infectious recombinant retrovirus under conditions appropriate for infection of the hepatocytes by recombinant retrovirus, thereby producing transduced hepatocytes.

Details for Patent 5,521,076

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Nps Pharmaceuticals, Inc.	NATPARA	parathyroid hormone	For Injection	125511	01/23/2015		2013-05-28